Skip to content

Study · Non-randomized trial · 2001

7 results

Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension.

Escorsell A, Bandi JC, Andreu V, Moitinho E, García-Pagán JC, Bosch J, Rodés J

Gastroenterology1 Jan 2001Cited by 131 (Europe PMC)

PMID11208725 (opens in a new tab)DOI10.1053/gast.2001.20892 (opens in a new tab)PepBankPUB-11208725
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients, octreotide injection transiently decreased portal pressure; the effect lasted only 5 minutes despite continuous infusion.

    In plain wordsIn cirrhotic patients, octreotide injection briefly lowered portal pressure from baseline, even with a continuous infusion.

    Peptide
    Octreotide
    Outcome
    DecreasePortal pressure after injection
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Duration of effect
    5 minutes
    octreotide injections, continuous infusions added

    Source sentences

    Summary
    Octreotide caused a marked and transient decrease in portal pressure and azygos blood flow and an increase in mean arterial pressure.
    2 context sentences
    Summary · context
    These effects lasted only 5 minutes despite addition of continuous octreotide infusions.
    Summary · context
    Splanchnic hemodynamics and plasma glucagon levels were measured in 68 cirrhotics in baseline conditions and (1) after a double-blind intravenous injection of octreotide (50 microg [n = 9] or 500 microg [n = 8]) or placebo (n = 7);
  2. 02HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients, octreotide injection transiently decreased azygos blood flow; the effect lasted only 5 minutes despite continuous infusion.

    In plain wordsIn cirrhotic patients, octreotide injection briefly lowered azygos blood flow from baseline, even with a continuous infusion.

    Peptide
    Octreotide
    Outcome
    DecreaseAzygos blood flow after injection
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Duration of effect
    5 minutes
    octreotide injections, continuous infusions added

    Source sentences

    Summary
    Octreotide caused a marked and transient decrease in portal pressure and azygos blood flow and an increase in mean arterial pressure.
    2 context sentences
    Summary · context
    These effects lasted only 5 minutes despite addition of continuous octreotide infusions.
    Summary · context
    Splanchnic hemodynamics and plasma glucagon levels were measured in 68 cirrhotics in baseline conditions and (1) after a double-blind intravenous injection of octreotide (50 microg [n = 9] or 500 microg [n = 8]) or placebo (n = 7);
  3. 03HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients, octreotide injection transiently increased mean arterial pressure; the effect lasted only 5 minutes despite continuous infusion.

    In plain wordsIn cirrhotic patients, octreotide injection briefly raised mean arterial pressure from baseline, even with a continuous infusion.

    Peptide
    Octreotide
    Outcome
    IncreaseMean arterial pressure after injection
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Measurements

    Duration of effect
    5 minutes
    octreotide injections, continuous infusions added

    Source sentences

    Summary
    Octreotide caused a marked and transient decrease in portal pressure and azygos blood flow and an increase in mean arterial pressure.
    2 context sentences
    Summary · context
    These effects lasted only 5 minutes despite addition of continuous octreotide infusions.
    Summary · context
    Splanchnic hemodynamics and plasma glucagon levels were measured in 68 cirrhotics in baseline conditions and (1) after a double-blind intravenous injection of octreotide (50 microg [n = 9] or 500 microg [n = 8]) or placebo (n = 7);
  4. 04HumanNon-randomized trialMechanism

    In cirrhotic patients, repeated octreotide injections produced shorter effects than the first bolus.

    In plain wordsIn cirrhotic patients, repeated octreotide injections had shorter effects than the first injection.

    Peptide
    Octreotide
    Outcome
    DecreaseRepeated injection effect duration
    Study

    n: not reported in source

    Comparator
    First octreotide bolus
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    50 microg injections · intravenousAs given in this study (human).

    Source sentences

    Summary
    Repeated octreotide injections had shorter, less marked effects than the first bolus.
    1 context sentence
    Summary · context
    (3) after repeated 50-microg injections of octreotide (n = 9) or placebo (n = 6) after an initial bolus (50 microg octreotide);
  5. 05HumanNon-randomized trialMechanism

    In cirrhotic patients, repeated octreotide injections produced less marked effects than the first bolus.

    In plain wordsIn cirrhotic patients, repeated octreotide injections had weaker effects than the first injection.

    Peptide
    Octreotide
    Outcome
    DecreaseRepeated injection effect magnitude
    Study

    n: not reported in source

    Comparator
    First octreotide bolus
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    50 microg injections · intravenousAs given in this study (human).

    Source sentences

    Summary
    Repeated octreotide injections had shorter, less marked effects than the first bolus.
    1 context sentence
    Summary · context
    (3) after repeated 50-microg injections of octreotide (n = 9) or placebo (n = 6) after an initial bolus (50 microg octreotide);
  6. 06HumanNon-randomized trialEfficacy outcome

    In cirrhotic patients, continuous octreotide infusion did not decrease portal pressure.

    In plain wordsIn cirrhotic patients, continuous octreotide infusion did not lower portal pressure from baseline.

    Peptide
    Octreotide
    Outcome
    No significant changePortal pressure during continuous infusion
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    A continuous octreotide infusion did not decrease portal pressure.
    1 context sentence
    Summary · context
    Splanchnic hemodynamics and plasma glucagon levels were measured in 68 cirrhotics in baseline conditions and (1) after a double-blind intravenous injection of octreotide (50 microg [n = 9] or 500 microg [n = 8]) or placebo (n = 7);
  7. 07HumanNon-randomized trialMechanism

    In cirrhotic patients, octreotide markedly reduced glucagon levels, which gradually returned to baseline despite continuous infusion or repeated injections.

    In plain wordsIn cirrhotic patients, octreotide lowered glucagon from baseline, but levels gradually returned despite continued dosing.

    Peptide
    Octreotide
    Outcome
    MixedGlucagon levels
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (human).

    Source sentences

    Summary
    Glucagon levels were markedly reduced by octreotide, but gradually returned to baseline despite continuous infusions or repeated injections of octreotide.
    1 context sentence
    Summary · context
    Splanchnic hemodynamics and plasma glucagon levels were measured in 68 cirrhotics in baseline conditions and (1) after a double-blind intravenous injection of octreotide (50 microg [n = 9] or 500 microg [n = 8]) or placebo (n = 7);

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.